deltatrials
Completed PHASE4 INTERVENTIONAL 4-arm NCT02025452

Novel Diagnostics and Probiotics to Improve Management of Paediatric Acute Gastroenteritis

Rapid Diagnostics and Probiotic Therapy for Paediatric Acute Gastroenteritis - a Randomized, Factorial, Controlled, Placebo-controlled, Pilot Trial

Sponsor: BioGaia AB

Updated 7 times since 2017 Last updated: Mar 23, 2017 Started: Mar 31, 2014 Primary completion: Nov 30, 2014 Completion: Dec 31, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02025452, this PHASE4 trial focuses on Acute Gastroenteritis and remains completed. Sponsored by BioGaia AB, it has been updated 7 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshotCompleted~Apr 2017 – ~Jun 2018 · 14 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

7 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

  5. Apr 2017 — Jun 2018 [monthly]

    Completed PHASE4

Show 2 earlier versions
  1. Feb 2017 — Apr 2017 [monthly]

    Completed PHASE4

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE4

    First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BioGaia AB
  • Grand Challenges Canada
  • Jeffrey Pernica
Data source: Hamilton Health Sciences Corporation

For direct contact, visit the study record on ClinicalTrials.gov .